Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease

PharmacoEconomics

Volumn 23, Issue 10, 2005, Pages 1031-1041

  Hughes, Dyfrig A ^a   Bodger, Keith ^b   Bytzer, Peter ^c   De Herdt, Dirk ^d   Dubois, Dominique ^d  

^a BANGOR UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ECONOMIC ASPECT; ENDOSCOPY; EVALUATION; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MALE; NON EROSIVE REFLUX DISEASE; PATIENT; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; SYMPTOM; UNITED KINGDOM;

ANTI-ULCER AGENTS; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PROTON PUMPS;

EID: 27744532756     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200523100-00006     Document Type: Article

References (23)

1. Kennedy T, Jones R. The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms. Aliment Pharmacol Ther 2000; 14: 1589-94
2. Ofman JJ. The economic and quality-of-life impact of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003; 98 (3 Suppl.): S8-S14
3. Jaspersen D, Kulig M, Labenz J, et al. Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD Study. Aliment Pharmacol Ther 2003; 17: 1515-20
4. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease: current concepts and dilemmas. Am J Gastroenterol 2001; 96: 303-14
5. Dent J, Jones R, Kahrilas P, et al. Management of gastro-oesophageal reflux disease in general practice. BMJ 2001; 322: 344-7
6. Inadomi JM. On-demand and intermittent therapy for gastro-oesophageal reflux disease: economic considerations. Pharmacoeconomics 2002; 20: 565-76
7. Wahlqvist P, Junghard O, Higgins A, et al. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies. Pharmacoeconomics 2002; 20: 267-77
8. Talley NJ, Venables TL, Green JR, et al. Esomeprazole 40mg and 20mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002; 14: 857-63
9. Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Aliment Pharmacol Ther 2001; 15: 347-54
10. Cooper AL, Baxter G. Efficacy of lansoprazole on demand therapy in the treatment of non-erosive reflux disease and functional ulcer-like dyspepsia [abstract]. Gut 2003; 52 Suppl. VI: A137
11. Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis: a placebo-controlled randomised trial. Aliment Pharmacol Ther 1999; 13: 907-14
12. Scholten T, Dekkers CPM, Schutze K, et al. On-demand therapy with pantoprazole 20mg as effective long-term management of reflux disease in patients with mild GERD: the ORION trial [abstract]. Gut 2002; 51 Suppl. III: A165
13. Kaspari S, Kupcinskas L, Fischer R, et al. On-demand therapy with pantoprazole 20mg as effective long-term management of patients suffering from mild GERD. Gastroenterology 2003; 124 (4 Suppl. 1): A538
14. Bytzer P, Blum AL, de Herdt D, et al. On-demand rabeprazole therapy provides heartburn control in long-term management of nonerosive reflux disease (NERD). Aliment Pharmacol Ther 2004; 19: 181-8
15. Kartman B, Gatz G, Johannesson M. Health state utilities in GERD patients with heartburn: a study in Germany and Sweden. Med Decis Making 2004; 23: 40-52
16. The EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208
17. Kind P, Hardman G, Macran S. UK Population norms for EQ-5D. York Centre for Health Economics Discussion Paper 1999 Nov, 172
18. Bodger K, Eastwood PG, Manning SI, et al. Dyspepsia workload in urban general practice and implications of the British Society of Gastroenterology Dyspepsia Guidelines (1996). Aliment Pharmacol Ther 2000; 14: 413-20
19. Department of Health. Drug tariff. London: The Stationary Office, 2003
20. Netten A, Rees T, Harrison G. Unit costs of health and social care 2001. Kent, UK: University of Kent at Canterbury, Personal Social Services Research Unit, 2001
21. Goeree R, O'Brien B, Hunt R, et al. Economic evaluation of long term management strategies for erosive oesophagitis. Pharmacoeconomics 1999; 16: 679-97
22. Gerson LB, Robbins AS, Garber A, et al. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95: 395-407
23. Harris RA, Kuppermann M, Richter JE. Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition. Am J Med 1997; 102: 78-88